NanoKTN member wins SET For Britain award
Medal awarded to ThaoNguyen Nguyen for Porphyrin-DNA poster
ThaoNguyen Nguyen was awarded the medal for her poster that looked at the use of Porphyrin-DNA as a scaffold for nanoarchitectures. The poster was judged the best chemistry presentation.
ThaoNguyen’s research focuses on the use of DNA as architecture for Porphyrin chromophore arrays (natural molecules found in heme or chlorophyll) for applications in future nanochips and potentially in photodynamic therapy for cancer treatment. The results show that DNA has great potential for the transformation from being a building block of life to being a building block for nanotechnology.
SET for Britain aims to encourage, support and promote Britain's early-stage and early-career research scientists, engineers and technologists to ensure continued progress in the development of UK research and r&d, and ultimately the future of UK business. The awards give early-career scientists the opportunity to communicate state-of-the-art science to Members of Parliament and scientific peers.
ThaoNguyen’s poster also won the EPSRC Award for Young Scientist at the UK Nano & Emerging Technologies Forum last year, hosted by the Nano Knowledge Transfer Network (NanoKTN) and UK Trade & Investment (UKTI). Being a NanoKTN member and winning the EPSRC Award contributed towards ThaoNguyen’s success at SET for Britain and has had a great impact on promoting her research.
‘Winning the Roscoe Medal and the EPSRC Award has given me opportunities to communicate my research to a broader audience, one that I would not normally expect to meet,’ she said.
‘Embedding an awareness within the next generation of current research will help to strengthen business and hopefully create further connections between academia and industry.’
Established by the Technology Strategy Board, the NanoKTN is managed by Centre for Process Innovation, a technology development and consulting company.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
UK clinical trial reforms come into force in largest regulatory overhaul in 20 years
The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Research & Development
Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer
The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
Research & Development
NEUVIOR Pharmaceuticals receives Innovate UK grant to explore bio-based materials for circular pharmaceutical manufacturing
The Innovate UK feasibility grant will advance its ZYLON programme, which involves clean-chemistry lab trials exploring how bio-derived materials could replace harder-to-recycle packaging formats and reduce waste in pharmaceutical manufacturing
Research & Development
Awen Oncology secures seven-figure funding to advance rare bone cancer therapeutic programme
The cancer therapeutics company has secured seven-figure funding led by biotech investor Dr Urs Spitz to progress its lead programme targeting a rare form of bone cancer with potential broader oncology applications towards clinical development